CDK4 and glioma: In glioma, circNEIL3 interacts with IGF2BP to inhibit the ubiquitin/proteasome-mediated degradation of IGF2BP3 to promote its protein expression and as well as that of its downstream targets, including CDK4/6, CD44 and c-MYC, thereby promoting malignant progression of glioma 73.